NVRO - Nevro Corp.
| Previous Close | 73.68 |
| Open | 74.07 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 73.58 - 76.05 |
| 52 Week Range | 65.00 - 94.34 |
| Volume | 415,661 |
| Avg. Volume | 437,833 |
| Market Cap | 2.269B |
| Beta | 0.01 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.25 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 93.70 |
- Bloomberg•7 days ago
Shocking the Spine Offers an Alternative to Opioids
Like millions of people caught up in America’s opioid crisis, Rick Surkin used to take a pill just to get out of bed in the morning. Until last year, the former firefighter relied on thrice-daily doses of the powerful painkiller OxyContin to numb the agony from a ruptured disc in his back. The series of tiny shocks, known as neuromodulation, has kept Surkin comfortable enough to ditch Oxy.
- GlobeNewswire•12 days ago
Recent Analysis Shows Paycom Software, American Renal Associates, Knowles, Timken, Nevro, and Unisys Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, May 15, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Paycom ...
- PR Newswire•13 days ago
Nevro Recognized as a "Best Place to Work" in the Bay Area
REDWOOD CITY, Calif., May 14, 2018 /PRNewswire/ - Nevro Corp. (NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has been named one of the "Best Places to Work" in the Bay Area by the San Francisco Business Times and the Silicon Valley Business Journal. Award applicants were evaluated and ranked highest across various categories including fun, collaborative culture, solid compensation, benefits offerings, as well as management practices.
- Thomson Reuters StreetEvents•18 days ago
Edited Transcript of NVRO earnings conference call or presentation 7-May-18 8:30pm GMT
Q1 2018 Nevro Corp Earnings Call
- Benzinga•19 days ago
Canaccord: Buy The Dip In Nevro After Disappointing Quarterly Report
Medical device manufacturer Nevro Corp (NYSE: NVRO )'s shares are tumbling after the company's first-quarter report after the close Monday. Nevro reported a wider-than-expected loss of 51 cents per share ...
- Motley Fool•19 days ago
Why Nevro Corp. Is Sinking Today
Shares tumble after the company reports first-quarter results. Here's what investors need to know.
- Associated Press•20 days ago
Nevro: 1Q Earnings Snapshot
REDWOOD CITY, Calif. (AP) _ Nevro Corp. (NVRO) on Monday reported a loss of $17.7 million in its first quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of 59 cents. The results missed Wall Street expectations.
- PR Newswire•20 days ago
Nevro Reports First Quarter 2018 Financial Results
REDWOOD CITY, Calif. , May 7, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today ...
- ACCESSWIRE•20 days ago
Nevro Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Nevro Corp. (NYSE: NVRO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 4:30 PM Eastern Time. To listen to the ...
- PR Newswire•25 days ago
Nevro to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
REDWOOD CITY, Calif. , May 2, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today ...
- PR Newswire•last month
Nevro to Report Operating Results for the First Quarter 2018
Nevro to Host Conference Call on Monday, May 7, 2018 at 1:30 p.m. PT / 4:30 p.m. ET REDWOOD CITY, Calif. , April 23, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that ...
Markit•last monthSee what the IHS Markit Score report has to say about Nevro Corp.
Short interest is moderately high for NVRO with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding NVRO totaled $57 million.
- CNBC•2 months ago
These medical devices are getting better at treating chronic pain
Spinal cord stimulation isn't as scary as it sounds. Innovation in the devices and a push away from treating chronic pain with opioids are causing the market to boom.
- PR Newswire•2 months ago
Full-Body MRI Conditional Labeling Now Available in United States for Nevro Senza® Spinal Cord Stimulation System
REDWOOD CITY, Calif., March 22, 2018 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that full-body magnetic resonance imaging (MRI) conditional labeling is now available in the United States for the Senza Spinal Cord Stimulation (SCS) System delivering HF10 therapy. This labeling expansion, which is now applicable in all our markets, adds to the previous labeling allowing head and extremity MRI scans, broadening the pool of patients who are eligible to receive the Senza SCS System. This approval is retroactive, meaning that the new labeling for expanded imaging applies to all patients currently implanted with the Senza SCS System and percutaneous leads. It is anticipated that a similar labeling expansion will follow for the Senza II SCS system.
Markit•2 months agoSee what the IHS Markit Score report has to say about Nevro Corp.
Short interest is moderately high for NVRO with between 10 and 15% of shares outstanding currently on loan. Over the last month, growth of ETFs holding NVRO is favorable, with net inflows of $4.13 billion.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NVRO earnings conference call or presentation 22-Feb-18 9:30pm GMT
Q4 2017 Nevro Corp Earnings Call
- PR Newswire•3 months ago
Nevro Reports Fourth Quarter and Full Year 2017 Financial Results and Provides 2018 Outlook
REDWOOD CITY, Calif. , Feb. 22, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today ...
- ACCESSWIRE•3 months ago
Nevro Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Nevro Corp. (NYSE: NVRO ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 4:30 PM Eastern Time. To ...
- Simply Wall St.•3 months ago
Nevro Corp’s (NYSE:NVRO) Earnings Declined -16.68%, But How Did It Fare Against The Industry?
Assessing Nevro Corp’s (NYSE:NVRO) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceedRead More...
- Zacks•3 months ago
Should You Buy Nevro (NVRO) Ahead of Earnings?
Nevro (NVRO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Markit•3 months agoSee what the IHS Markit Score report has to say about Nevro Corp.
Short interest is moderately high for NVRO with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding NVRO totaled $133 million.
- PR Newswire•4 months ago
Nevro to Report Operating Results for the Fourth Quarter and Full Year 2017
Nevro to Host Conference Call on Thursday, February 22, 2018 at 1:30 p.m. PT / 4:30 p.m. ET REDWOOD CITY, Calif. , Feb. 8, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company ...
Markit•4 months agoSee what the IHS Markit Score report has to say about Nevro Corp.
Nevro Corp NYSE:NVRO
Market Realist•4 months agoWhat’s ahead for Abbott Laboratories’ Medical Device Unit?
What's Next for Abbott Laboratories after a Stellar 2017?
